HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $17
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $17.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $17.
